Regeneron (REGN) stock trades up, here is why

Regeneron Pharmaceuticals (REGN) reached a 52-week high after reporting Q3 net sales of $5.1B, up 36% YoY, driven by Dupixent. Analysts noted strong performance across key products, with mixed ratings and price targets.

Regeneron Pharmaceuticals reported Q3 2026 adjusted EPS of $20.07, beating estimates. Revenue rose 36% YoY to $5.12B, driven by Dupixent, Eylea HD, and Libtayo. Eylea HD sales grew 62% YoY, while legacy Eylea declined 41%. Collaboration revenues surged 52% YoY to $3.00B. The company raised R&D expense guidance but lowered SG&A expense guidance. According to Zacks Investment Research, shares rose on the results.

Regeneron reported Q3 2026 revenue of $5.116B, up 36% YoY, with GAAP net income rising 33% to $1.949B. Key products like Dupixent and EYLEA HD saw significant sales growth. The company expanded its Sanofi collaboration, receiving a $1B upfront payment. Regeneron also advanced its pipeline with FDA approvals and positive clinical trial results. The stock is up 11.46%.

Regeneron (REGN) reported Q3 earnings, highlighting pipeline milestones. The company expects an FDA decision for cemdisiran in November and plans to present initial data for its CIDEB-targeting siRNA. It also reported positive results for ubamatamab in ovarian cancer. Sanofi collaboration revenue reached $2.7B, with a $1B upfront payment expected in Q4. Regeneron generated $2.9B in free cash flow and plans $3B in share repurchases for the year.

Regeneron reported Q3 2026 earnings, with total revenue up 36% and non-GAAP EPS up 70% YoY. Key drugs Dupixent, EYLEA HD, and Libtayo set sales records. Dupixent global sales reached $6.5B, EYLEA HD U.S. sales hit $700M, and Libtayo global sales were $550M. The company highlighted pipeline progress in neuromuscular, metabolic, and oncology areas, with potential blockbuster opportunities.

Regeneron (REGN) shares surged 13.55% to $929.69 after reporting Q3 earnings. Non-GAAP EPS was $20.07, beating estimates, and revenue rose 36.27% YoY to $5.1158B. Management raised full-year gross margin guidance. The stock is held by several health care ETFs, including XLV, XBI, IBB, and VHT, which may benefit from the rally.